Stada-Arzneimittel AG (STADA) operates in the field of marketing active ingredients. The company markets multisource products that is products with active ingredients that are off-patent and free of other commercial property rights. It focuses on off-patent active ingredients, known as ‘multisource products’. It offers doctors, pharmacies and patients a range of products for various indications. The company operates in three segments: Generics, Branded products, and Special pharmaceuticals. The company also engages in non core activities such as commercial business to support or supplement the core segments. Generics Segment Generics are drugs which, after expiration of the patent or other relevant commercial property rights, are offered in the same quality. The Group’s selling active ingredient in the Generics core segment is the stomach medication Omeprazole. In Germany, the Group's generic drugs are marketed under the STADA brand and also by the Group subsidiary ALIUD PHARMA. The range of these two sales lines covers all of the important indications and dosage forms. With generics and branches in Belgium, Denmark, France, the United Kingdom, Ireland, Italy, Kazakhstan, the Netherlands, Austria, Portugal, Russia, Switzerland, Spain, Ukraine and the Czech Republic, STADA represents in European markets with its own sales lines for generics. In the USA also STADA is active in the generics market with its own sales company. Branded Products Segment STADA’s branded products are the drugs or health care products that the Group offers under a product-specific brand name. In this segment, STADA concentrates on multisource products that are accessible without own active ingredient research. The Branded Products portfolio includes both non-prescription over-the-counter or OTC products and prescription drugs. STADA's subsidiaries sell their branded products in Germany, Austria, Belgium, China, Czech Republic, France, Ireland, Italy, Kazakhstan, the Netherlands, Portugal, Russia, Spain, Switzerland, Thailand, Ukraine, USA and Vietnam. Special Pharmaceuticals Segment Special Pharmaceuticals is the third and smallest core segment of STADA. Special pharmaceuticals at STADA include products that are distinguished from the general pharmaceutical market by specific market entry barriers, indication areas, or market and sales requirements. In the Special Pharmaceuticals segment, STADA concentrates on products that are accessible for marketing without own active ingredient research. The segment consists of drugs for cancer therapy, so-called oncology products. Strategic Acquisitions/Partnerships STADA acquired Nizhpharm OJSC, a Russian pharmaceutical company on November 8, 2004. STADA entered in to a strategic partnership with LipoNova GmbH, Hanover, in the field of tumor vaccines in fiscal 2004.
stada arzneimittel ag (SAZ:Xetra)
Bad Vilbel, 61118
Phone: 49 6101 6030
Fax: 49 6101 603 259www.stada.de
|BTG PLC||603.50 GBp||-2.50|
|Richter Gedeon Nyrt||3,949||+49.00|
|Impax Laboratories Inc||$27.87 USD||-0.29|
|Skyepharma PLC||245.00 GBp||-0.75|
|Vernalis PLC||32.13 GBp||0.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact STADA ARZNEIMITTEL AG, please visit www.stada.de. Company data is provided by Capital IQ. Please use this form to report any data issues.